Identification of a common docking topology with substantial variation among different TCR-peptide-MHC complexes

Current Biology : CB
M K TengJ H Wang

Abstract

Whether T-cell receptors (TCRs) recognize antigenic peptides bound to major histocompatability complex (MHC) molecules through common or distinct docking modes is currently uncertain. We report the crystal structure of a complex between the murine N15 TCR [1-4] and its peptide-MHC ligand, an octapeptide fragment representing amino acids 52-59 of the vesicular stomatitis virus nuclear capsid protein (VSV8) bound to the murine H-2Kb class I MHC molecule. Comparison of the structure of the N15 TCR-VSV8-H-2Kb complex with the murine 2C TCR-dEV8-H-2Kb [5] and the human A6 TCR-Tax-HLA-A2 [6] complexes revealed a common docking mode, regardless of TCR specificity or species origin, in which the TCR variable Valpha domain overlies the MHC alpha2 helix and the Vbeta domain overlies the MHC alpha1 helix. As a consequence, the complementary determining regions CDR1 and CDR3 of the TCR Valpha and Vbeta domains make the major contacts with the peptide, while the CDR2 loops interact primarily with the MHC. Nonetheless, in terms of the details of the relative orientation and disposition of binding, there is substantial variation in TCR parameters, which we term twist, tilt and shift, and which define the variation of the V module of the TCR r...Continue Reading

References

Mar 1, 1991·Acta Crystallographica. Section A, Foundations of Crystallography·T A JonesM Kjeldgaard
Dec 27, 1996·The Journal of Biological Chemistry·J LiuE L Reinherz

❮ Previous
Next ❯

Citations

Dec 5, 2002·Chembiochem : a European Journal of Chemical Biology·Björn HolmJan Kihlberg
Aug 30, 2008·Immunologic Research·Edward J Collins, David S Riddle
Apr 17, 2002·Molecular Immunology·Jia-huai Wang, Ellis L Reinherz
Jan 16, 2002·Current Opinion in Immunology·Markus G Rudolph, Ian A Wilson
Dec 15, 2000·Current Opinion in Structural Biology·J Wang, E L Reinherz
Dec 23, 1999·Current Opinion in Structural Biology·K Maenaka, E Y Jones
Feb 19, 1999·Immunity·D N Garboczi, W E Biddison
May 4, 2001·Microbes and Infection·P Le Bouteiller, C Solier
Nov 18, 2006·Nature Reviews. Immunology·Stephen J TurnerJamie Rossjohn
May 15, 2001·Immunology and Cell Biology·M Regner
Jan 20, 1999·The Journal of Experimental Medicine·R ZhaoE J Collins
Jan 5, 2011·The Journal of Experimental Medicine·Dhruv K SethiKai W Wucherpfennig
Jun 8, 1999·Annual Review of Immunology·K C GarciaI A Wilson
Jun 8, 1999·Annual Review of Immunology·E SebzdaP S Ohashi
Mar 29, 2000·Biochemical and Biophysical Research Communications·P GogolákG K Tóth
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·H W KesselsT N Schumacher
Jun 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·M H HeemskerkJ H Falkenburg
Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y GhendlerE L Reinherz
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·B K ChoH N Eisen
Feb 13, 2001·Immunity·M Correia-NevesC Benoist
Sep 18, 2016·Protein & Cell·Xiaolong LiJia-Huai Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.